Boston Scientific’s portfolio and pipeline, of transcatheter structural heart valve therapies, tools, clinical evidence and training is designed to help you:
- Improve quality outcomes while reducing the risk of transcatheter aortic valve replacement (TAVR)-related stroke and complications
- Improve operational efficiencies through meaningful innovation, training, and education to expand on clinicians’ and lab staff’s expertise
- Advance your structural heart program with creative healthcare solutions and partnerships providing value beyond our market-leading products
Commitment to a patient-first mentality
Learn more about our structural heart vision and how it benefits your patients and your cardiovascular service line (CVSL).
Protection from stroke
Boston Scientific is the first and only company to offer Protected TAVR™ with SENTINEL™ Cerebral Protection System enabling you to reduce the risk of TAVR-related stroke — a devastating outcome for patients and the healthcare system.

SENTINEL™ Cerebral Protection System


High cost associated with stroke during TAVR
23%
Increase ($12,737) in average TAVR index hospitalization costs5
4.2
Average increase in length of stay (LOS)5
70%
Increase in cumulative 1-year healthcare costs (additional $59,646)5
31%
Higher 30-day readmission rates (20.5% vs 15.6%)6
References:
1. Van Mieghem N. presented at TVT 2018; Chakravarty T. presented at TVT 2018
2. Kapadia SR. et al. J Am Coll Cardiol. 2017 Jan 31;69(4):367-377
3. Seeger J et al. 2017. JACC Cardiovasc Interv. 10(22)2297-2303
4. Alkhouli, M, et al. “Cost of procedural stroke in TAVR in a US Medicare population” Valve20A-POS01; PCR London Valves 2020
5. Alqahtani F, et al. Clinical and Economic Burden of Acute Ischemic Stroke Following Transcatheter Aortic Valve Replacement SHJ online 16 Nov 2018
6. SENTINEL US IDE trial data presented at the SENTINEL CPS FDA Advisory Panel, February 23, 2017